No Detail Found!

Effect of Docetaxel Combined with Cisplatin Preoperative Neoadjuvant Chemotherapy for Stage III NSCLC

Author(s)
Guocheng Ma Department of Respiratory, Lanzhou General Hospital, Lanzhou Military Area Command,730000,China
Wei Chen Department of Respiratory, Lanzhou General Hospital, Lanzhou Military Area Command,730000,China
Minquan Ma Department of Emergency, Lanzhou General Hospital, Lanzhou Military Area Command,730000,China
Abstract
The aim of this study was to investigate the effect of docetaxel plus cisplatin preoperative neoadjuvant chemotherapy in stage III non-small cell lung cancer (NSCLC). It was an analytical study carried out from May 2013 to May 2017. Eightytwo patients with stage III NSCLC were divided into Group A and B according to a random number table (n=41). Group A received neoadjuvant chemotherapy with docetaxel plus cisplatin before surgery. Group B underwent surgical treatment after preoperative examination. Compared with group B,operation time of group A was shorter (p<0.001); intraoperative blood loss of group A was lower (p<0.001); surgical resection rate and 1-year survival rate in group A were higher (p=0.013, 0.023). This suggested that preoperative neoadjuvant chemotherapy with docetaxel plus cisplatin may improve surgical resection rate, shorten operation time, reduce intraoperative blood loss, and prolong survival of patients.
Publication Details
Page(s) 1230-1231
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 29, Issue: 12, Year: 2019

Request the full text from PASTIC

Keywords
Cisplatin, Docetaxel, Neoadjuvant chemotherapy, Stage III non-small cell lung cancer
0

Citations

0

Downloads

76

Views